bioXXmed Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
bioXXmed's earnings have been declining at an average annual rate of -60.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.8% per year.
Anahtar bilgiler
-60.3%
Kazanç büyüme oranı
-47.8%
EPS büyüme oranı
Biotechs Sektör Büyümesi | -14.6% |
Gelir büyüme oranı | -14.8% |
Özkaynak getirisi | -19,469.0% |
Net Marj | -420,594.5% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Gelir ve Gider Dağılımı
bioXXmed nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -21 | 0 | 0 |
31 Mar 24 | 0 | -21 | 0 | 0 |
31 Dec 23 | 0 | -21 | 0 | 0 |
30 Sep 23 | 0 | -11 | 0 | 0 |
30 Jun 23 | 0 | -1 | 0 | 0 |
31 Mar 23 | 0 | -1 | 0 | 0 |
31 Dec 22 | 0 | -1 | 0 | 0 |
30 Sep 22 | 0 | -2 | 0 | 0 |
30 Jun 22 | 0 | -4 | 0 | 0 |
31 Mar 22 | 0 | -4 | 0 | 0 |
31 Dec 21 | 0 | -4 | 1 | 0 |
30 Sep 21 | 0 | -3 | 1 | 0 |
30 Jun 21 | 0 | -2 | 1 | 0 |
31 Mar 21 | 0 | -2 | 1 | 0 |
31 Dec 20 | 0 | -2 | 1 | 0 |
30 Sep 20 | 0 | -2 | 1 | 0 |
30 Jun 20 | 0 | -1 | 1 | 0 |
31 Mar 20 | 0 | -1 | 0 | 0 |
31 Dec 19 | 0 | -1 | 0 | 0 |
30 Sep 19 | 0 | -1 | 0 | 0 |
30 Jun 19 | 0 | -1 | 0 | 0 |
31 Mar 19 | 0 | -1 | 0 | 0 |
31 Dec 18 | 0 | -1 | 0 | 0 |
30 Sep 18 | 0 | -1 | 0 | 0 |
30 Jun 18 | 0 | -1 | 0 | 0 |
31 Mar 18 | 0 | -1 | 0 | 0 |
31 Dec 17 | 0 | -1 | 0 | 0 |
30 Sep 17 | 0 | -1 | 0 | 0 |
30 Jun 17 | 0 | -1 | 0 | 0 |
31 Mar 17 | 0 | -1 | 0 | 0 |
31 Dec 16 | 0 | -1 | 0 | 0 |
30 Sep 16 | 0 | -1 | 0 | 0 |
30 Jun 16 | 0 | -1 | 0 | 0 |
31 Mar 16 | 0 | -1 | 0 | 0 |
31 Dec 15 | 0 | -1 | 0 | 0 |
30 Sep 15 | 0 | -1 | 0 | 0 |
30 Jun 15 | 0 | -1 | 0 | 0 |
31 Mar 15 | 0 | -1 | 0 | 0 |
31 Dec 14 | 0 | -1 | 0 | 0 |
30 Sep 14 | 0 | -1 | 0 | 0 |
30 Jun 14 | 0 | -1 | 0 | 0 |
31 Mar 14 | 0 | -1 | 1 | 0 |
31 Dec 13 | 0 | -1 | 1 | 0 |
Kaliteli Kazançlar: T5O is currently unprofitable.
Büyüyen Kar Marjı: T5O is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: T5O is unprofitable, and losses have increased over the past 5 years at a rate of 60.3% per year.
Büyüme Hızlandırma: Unable to compare T5O's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: T5O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Özkaynak Getirisi
Yüksek ROE: T5O has a negative Return on Equity (-19469.04%), as it is currently unprofitable.